SCHEMBL1269262

SCHEMBL1269262

Cc1cc(N2CCCC2)n[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.50
GAA P10253 5/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
NPC1 O15118 1/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
HPGD P15428 1/20 0.50
RAB9A P51151 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
IGF1R P08069 2/20 0.40
CASP1 P29466 1/20 0.40
CASP4 P49662 1/20 0.40
CASP5 P51878 1/20 0.40
HRH4 Q9H3N8 2/20 0.39
L3MBTL1 Q9Y468 3/20 0.38
HTT P42858 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31466596 0.84 CASP1 (0.46) ALDH1A1CASP1CASP4CASP5HRH4
SCHEMBL14822948 0.82 KMT2A (0.49) KDM4EGAASMN1; SMN2ALDH1A1HPGD
SCHEMBL31466460 0.76 ALDH1A1 (0.47) KDM4EGAASMN1; SMN2NPC1ALDH1A1
SCHEMBL31466248 0.76 RET (0.43) SMN1; SMN2NPC1RAB9ACRHBPCRHR2
SCHEMBL1493339 0.75 SMN1; SMN2 (0.50) KDM4EGAASMN1; SMN2NPC1ALDH1A1
SCHEMBL19924700 0.73 SMN1; SMN2 (0.53) KDM4EGAASMN1; SMN2NPC1ALDH1A1
Hydrochloric Acid SCHEMBL923005 0.73 SMN1; SMN2 (0.49) KDM4EGAASMN1; SMN2NPC1ALDH1A1
SCHEMBL13663859 0.71 HSD17B10 (0.44) ALDH1A1HSD17B10L3MBTL1CYP1A2CYP2D6
SCHEMBL29099923 0.70 MAP3K7 (0.34) AURKAAURKBPDE10A
SCHEMBL15822827 0.68 ALDH1A1 (0.47) KDM4EGAASMN1; SMN2NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110124623-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-05-26 US disclosed
US-7879855-B2 administering (S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide, for the treatment of cancers of the colon, lung, ovary, and pancreas; anticarcinogenic agents BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124623-A1 PYRROLOTRIAZINE KINASE INHIBITORS STK25, STK17A, STK35 KDM4E 876/4885GAA 879/4885SMN1; SMN2 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.